Table 2 Baseline characteristics of the 1 L ARROW trial participants given pralsetinib and Flatiron EDM cohort given 1 L pembrolizumab, and 1 L pembrolizumab with chemotherapy without adjustment; balanced variables are those with SMD < 0.1.
Level | Pembrolizumab | Pralsetinib | SMD | Pembrolizumab with chemotherapy | Pralsetinib | SMD | |
|---|---|---|---|---|---|---|---|
N | 686 | 109 | 1270 | 109 | |||
Age (%) | <65 | 197 (28.7) | 65 (59.6) | 0.655 | 508 (40.0) | 65 (59.6) | 0.4 |
>=65 | 489 (71.3) | 44 (40.4) | 762 (60.0) | 44 (40.4) | |||
Sex (%) | F | 375 (54.7) | 59 (54.1) | 0.011 | 569 (44.8) | 59 (54.1) | 0.187 |
M | 311 (45.3) | 50 (45.9) | 701 (55.2) | 50 (45.9) | |||
Smoking history at baseline (%) | History of smoking | 628 (91.5) | 43 (39.4) | 1.31 | 1144 (90.1) | 43 (39.4) | 1.25 |
No history of smoking | 58 (8.5) | 66 (60.6) | 126 (9.9) | 66 (60.6) | |||
ECOG (%) | 0 | 230 (33.5) | 34 (31.2) | 0.05 | 512 (40.3) | 34 (31.2) | 0.191 |
1 | 456 (66.5) | 75 (68.8) | 758 (59.7) | 75 (68.8) | |||
Time from initial diagnosis to first dose (months) (median [IQR]) | 1.41 [0.92, 2.85] | 1.74 [1.25, 2.30] | 0.054 | 1.18 [0.76, 1.84] | 1.74 [1.25, 2.30] | 0.148 | |
Stage at initial diagnosis (%) | STAGE I, II, or III | 192 (28.0) | 17 (15.6) | 0.304 | 204 (16.1) | 17 (15.6) | 0.013 |
STAGE IV | 494 (72.0) | 92 (84.4) | 1066 (83.9) | 92 (84.4) | |||
Race (%) | White | 493 (71.9) | 54 (49.5) | 0.612 | 883 (69.5) | 54 (49.5) | 0.573 |
Other | 123 (17.9) | 49 (45.0) | 248 (19.5) | 49 (45.0) | |||
Unknown | 70 (10.2) | 6 (5.5) | 139 (10.9) | 6 (5.5) | |||
Brain/CNS metastasis only (%) | 0 | 597 (87.0) | 79 (72.5) | 0.368 | 1090 (85.8) | 79 (72.5) | 0.333 |
1 | 89 (13.0) | 30 (27.5) | 180 (14.2) | 30 (27.5) |
